Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.

ABSTRACT:

Objective

To determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with covid-19.

Design

Randomised, double blind, placebo controlled trial.

Setting

Three Canadian provinces (Quebec, Ontario, and British Columbia).

Participants

203 adults aged 18 years and older with polymerase chain reaction confirmed covid-19, presenting with fever, cough, or dyspnoea.

Intervention

Participants were randomised to receive either inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) or metered dose inhaler and nasal saline placebos for 14 days.

Main outcome measures

The primary outcome was symptom resolution at day 7. Analyses were conducted on the modified inten

SUBMITTER: Ezer N 

PROVIDER: S-EPMC8561042 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature